Effects of Adjunct Low-Dose Vitamin D on Relapsing-Remitting Multiple Sclerosis Progression: Preliminary Findings of a Randomized Placebo-Controlled Trial
Table 1
Characteristics of patients with relapsing-remitting multiple sclerosis who received low-dose vitamin D (0.5 μg/day) or placebo at baseline.
Characteristics
Treatment group at baseline
Differences (95% CI)
Vitamin D Mean (SD)
Placebo Mean (SD)
Age (years)
38.6 (8.4)
37.9 (7.9)
0.7 (−3.9, 5.3)
Duration of multiple sclerosis (years)
4.5 (2.7)
4.1 (1.7)
0.4 (−0.9, 1.7)
EDSS at baseline
1.6 (0.7)
1.7 (1.2)
−0.1 (−0.7, 0.5)
Relapses in previous year
1.04 (0.2)
1.04 (0.2)
0.0 (−0.1, 0.1)
No. (%)
No. (%)
Gender
Men
3 (12.0)
3 (12.0)
0.0 (−18.0, 18.0)
Women
22 (88.0)
22 (88.0)
—
Concomitant medications
Interferon beta
22 (88.0)
21 (84.0)
4.0 (−15.2, 23.2)
Statin
2 (8.0)
3 (12.0)
−4.0 (−20.6, 12.6)
Immunosuppressive drug
1 (4.0)
1 (4.0)
0.2 (−10.9, 10.9)
EDSS at baseline
≤1.5
15 (60.0)
18 (72.0)
−12.0 (−38.0, 14.0)
2.0–2.5
8 (32.0)
4 (16.0)
16.0 (−7.3, 39.3)
≥3.0
2 (8.0)
3 (12.0)
−4.0 (−20.6, 12.6)
Relapses in previous year
1
24 (96.0)
24 (96.0)
0.0 (−10.9, 10.9)
2
1 (4.0)
1 (4.0)
0.0 (−10.9, 10.9)
CI: confidence interval, EDSS: expanded disability status scale.
